PURPOSE: To establish an inverse planning set of parameters (class solution) to boost dominant intra-prostatic lesion (DIL) defined by MRI/MRSI. METHODS: For 15 patients, DIL were contoured on CT or MR images and a class solution was developed to boost the DIL under the dosimetric requirements of the RTOG-0321 protocol. To determine the maximum attainable level of boost for each patient, 5 different levels were considered, at least 110%, 120%, 130%, 140% and 150% of the prescribed dose. The maximum attainable level was compared to the plan without boost using cumulative dose volume histogram (DVH). RESULTS: DIL dose escalation was feasible for 11/15 patients under the requirements. The planning target volume (PTV) dose was slightly increased, while the DIL dose was significantly increased without any violation of requirements. With slight adjustments of the dose constraint parameters, the dose escalation was feasible for 13/15 patients under requirements. CONCLUSION: Using a class solution, a dose escalation of the MRI/MRSI defined DIL up to 150% while complying with RTOG dosimetric requirements is feasible. This HDR brachytherapy approach to dose escalation allows a significant dose increase to the tumor while maintaining an acceptable risk of complications.
PURPOSE: To establish an inverse planning set of parameters (class solution) to boost dominant intra-prostatic lesion (DIL) defined by MRI/MRSI. METHODS: For 15 patients, DIL were contoured on CT or MR images and a class solution was developed to boost the DIL under the dosimetric requirements of the RTOG-0321 protocol. To determine the maximum attainable level of boost for each patient, 5 different levels were considered, at least 110%, 120%, 130%, 140% and 150% of the prescribed dose. The maximum attainable level was compared to the plan without boost using cumulative dose volume histogram (DVH). RESULTS: DIL dose escalation was feasible for 11/15 patients under the requirements. The planning target volume (PTV) dose was slightly increased, while the DIL dose was significantly increased without any violation of requirements. With slight adjustments of the dose constraint parameters, the dose escalation was feasible for 13/15 patients under requirements. CONCLUSION: Using a class solution, a dose escalation of the MRI/MRSI defined DIL up to 150% while complying with RTOG dosimetric requirements is feasible. This HDR brachytherapy approach to dose escalation allows a significant dose increase to the tumor while maintaining an acceptable risk of complications.
Authors: György Kovács; Richard Pötter; Tillmann Loch; Josef Hammer; Inger-Karine Kolkman-Deurloo; Jean J M C H de la Rosette; Hagen Bertermann Journal: Radiother Oncol Date: 2005-02 Impact factor: 6.280
Authors: Juyoung A Jung; Fergus V Coakley; Daniel B Vigneron; Mark G Swanson; Aliya Qayyum; Vivian Weinberg; Kirk D Jones; Peter R Carroll; John Kurhanewicz Journal: Radiology Date: 2004-12 Impact factor: 11.105
Authors: I-Chow Hsu; Daniel Hunt; William Straube; Jean Pouliot; Adam Cunha; Devan Krishnamurthy; Howard Sandler Journal: Pract Radiat Oncol Date: 2013-03-29
Authors: Martin T King; Nicola J Nasser; Nitin Mathur; Gil'ad N Cohen; Marisa A Kollmeier; Jasper Yuen; Hebert A Vargas; Xin Pei; Yoshiya Yamada; Kristen L Zakian; Marco Zaider; Michael J Zelefsky Journal: Brachytherapy Date: 2016-04-20 Impact factor: 2.362
Authors: Galen Reed; J Adam Cunha; Susan Noworolski; John Kurhanewicz; Daniel Vigneron; I-Chow Hsu; Jean Pouliot Journal: J Contemp Brachytherapy Date: 2011-03-31